Drug Trial Radar · NCT05091424
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
332
Planned (sponsor's estimate)
Start
Mar 7, 2022
Primary completion
Feb 10, 2031
Study completion Feb 10, 2032
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed by the treating physician to continue their BTKi throughout the screening period and for the first three cycles of mosunetuzumab. An additional arm (open to non-US participants only) has been added to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with venetoclax, a B-cell lymphoma 2 (BCL2) inhibitor, compared to standard-of-care rituximab plus venetoclax.
Conditions
- Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
MosunetuzumabDrug
Participants will receive subcutaneous (SC) mosunetuzumab.
TocilizumabDrug
Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.
VenetoclaxDrug
Participants will receive daily oral venetoclax.
RituximabDrug
Participants will receive IV rituximab as per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Dose-Limiting Toxicities (DLTs)Time frame: From the first administration of mosunetuzumab until 21 days after the final mosunetuzumab step-up dose for Arms A, B, and C (up to 3 months)
- Objective Response Rate (ORR) During Dose Expansion PhaseTime frame: Up to 8-12 weeks after the last dose of study drug
Locations
31 sites in 10 countries. Site status is shown where the registry gives one.
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Withdrawn
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
Uni of Texas - Md Anderson Cancer Center
Houston, Texas · Withdrawn
Huntsman Cancer Institute at The University of Utah
Salt Lake City, Utah · Recruiting
Princess Alexandra Hospital Woolloongabba
Woolloongabba, Queensland, Australia · Recruiting
Peter MacCallum Cancer Center
East Melbourne, Victoria, Australia · Completed
Monash Medical Centre
Melbourne, Victoria, Australia · Recruiting
Peking University People's Hospital
Beijing, China · Recruiting
Southern Medical University Nanfang Hospital
Guangzhou, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
Tianjin Institute of Hematology & Blood Diseases Hospital
Tianjin, China · Recruiting
Chu de Clermont Ferrand
Clermont-Ferrand, France · Withdrawn
IUCT Oncopole
Toulouse, France · Withdrawn
Universitätsklinikum Augsburg
Augsburg, Germany · Recruiting
Uniklinik Koln
Cologne, Germany · Withdrawn
Universitätsklinikum Ulm
Ulm, Germany · Withdrawn
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili
Brescia, Lombardy, Italy · Recruiting
Osp. San Raffaele
Milan, Lombardy, Italy · Recruiting
Asst Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, Italy · Recruiting
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
Sant'Andrea Delle Fratte (PG), Umbria, Italy · Recruiting
Uniwersyteckie Centrum Kliniczne
Gda?sk, Poland · Recruiting
PRATIA MCM Kraków
Krakow, Poland · Recruiting
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
Wroc?aw, Poland · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Seoul St Mary's Hospital
Seoul, South Korea · Recruiting
Yeouido St. Mary's Hospital
Seoul, South Korea · Recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Christie Hospital NHS Trust
Manchester, United Kingdom · Recruiting
Churchill Hospital
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.